CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Evacetrapib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01810432
NCT01810432Phase 1Completed
CompareCT.gov

Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects

Eli Lilly and Company·interventional·Posted Mar 13, 2013·Updated Oct 12, 2018

In Brief

A Phase 1 clinical trial evaluating Evacetrapib and High-fat Meal for Healthy Volunteers. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected. The study has 2 periods. In each period, participants will take the study drug for 10 days, either with or without a meal. There is a minimum 14-day washout between each period. This study is approximately 50 days, not including screening. Screening is required within 28 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 13, 2013
Enrollment StartMar 1, 2013
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.3 years ago

Interventions

Evacetrapibdrug

Administered orally

High-fat Mealother

Administered orally, at breakfast.